ArticleResearch square2023

Vactosertib, a novel TGF-β1 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma.

Ehsan Malek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.